UBS Group reaffirmed their neutral rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Monday, www.boersen-zeitung.de reports.
Several other equities analysts also recently commented on the stock. Deutsche Bank reiterated a buy rating and issued a GBX 5,700 ($77.30) price objective on shares of AstraZeneca in a report on Thursday, January 11th. Citigroup reiterated a buy rating and issued a GBX 6,000 ($81.37) price objective on shares of AstraZeneca in a report on Wednesday, January 10th. JPMorgan Chase & Co. set a GBX 5,500 ($74.59) price objective on shares of AstraZeneca and gave the company a buy rating in a report on Thursday, January 4th. Barclays reiterated an overweight rating and issued a GBX 6,300 ($85.44) price objective on shares of AstraZeneca in a report on Monday, December 18th. Finally, Bryan, Garnier & Co reiterated a buy rating on shares of AstraZeneca in a report on Friday, December 15th. Four equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of GBX 5,219 ($70.78).
Shares of AstraZeneca (AZN) traded up GBX 62.50 ($0.85) on Monday, reaching GBX 5,043 ($68.39). 2,588,291 shares of the company were exchanged, compared to its average volume of 1,610,000. The firm has a market capitalization of $63,860.00 and a P/E ratio of 2,508.96. AstraZeneca has a fifty-two week low of GBX 4,136.50 ($56.10) and a fifty-two week high of GBX 5,520 ($74.86).
WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3146018/ubs-group-reaffirms-neutral-rating-for-astrazeneca-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.